BOLD News and Press, Audentes Therapeutics Inc. From 10/08/19

The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stoc...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

- First seven treated patients now ventilator independent and able to rise to a standing position or walk - Continued significant and durable improvements in respiratory function and developmental motor milestones in all treated patients - AT132 continues to be generally well-tol...

- Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1 and the first treated patients in dose Cohort 2 - Additional presentations include data from INCEPTUS, a prospective natural history run-in study to characterize the cl...

Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...

Company Thesis Audentes Therapeutics' ( BOLD ) flagship candidate AT-132 has shown very good risk-reward profile in the treatment of newborns with X-linked Myotubular Myopathy (XLMTM). The therapy has amazing efficacy; immunogenicity profile, genotoxicity profile, and demonstrated satisfacto...

Audentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Conference Call August 06, 2019 04:30 PM ET Company Participants Andrew Chang - Head, IR Matt Patterson - Chairman and Chief Executive Officer Natalie Holles - President and Chief Operating Officer Tom Soloway - Executive Vice...

Audentes Therapeutics (NASDAQ: BOLD ): Q2 GAAP EPS of -$1.01 beats by $0.06 . More news on: Audentes Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO , Aug. 6, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today reported its financial results for ...